PMID- 1933275
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20190613
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 553
IP  - 1
DP  - 1991 Jul 5
TI  - Leukotrienes in brain: natural occurrence and induced changes.
PG  - 4-13
AB  - Peptidoleukotrienes (SP-LTs) (both total product and individual LTC4 and LTE4 and 
      LTB4 were measured by radioimmunoassay in cerebrospinal fluid (CSF) collected 
      from the third ventricle of conscious cats. Total SP-LT was expressed as LTE4 
      after treating samples with crude gamma-glutamyltranspeptidase. Prostaglandin 
      (PG) E2 and thromboxane (TX) B2, the stable metabolite of TXA2, were also assayed 
      in part of the experiments. Under basal conditions, SP-LT and LTC4 were 
      consistently measurable (respectively, 327 +/- 14 and 244 +/- 41 pg/ml), while 
      native LTE4 was below the threshold of the assay (60-280 pg/ml) in most cases. 
      LTB4 was barely detectable (30 +/- 2 pg/ml) or not detectable at all. PGE2 was 
      normally less abundant than TXB2 (31 +/- 4 vs 281 +/- 47 pg/ml). 
      Intracerebroventricular (i.c.v.) administration of arachidonic acid (40 
      microgram) caused a 4-fold increase in SP-LT levels which was relatively small 
      and transient compared to PGE2 (76-fold) and TXB2 (23-fold), while there was no 
      change in either native LTE4 or LTB4. A similar response was obtained with 
      platelet-activating factor (PAF, 1 microgram i.c.v.), though SP-LT elevation 
      (4-fold) was more persistent. A further rise in SP-LT (9-fold) was noted when PAF 
      administration was preceded by indomethacin (500 microgram i.c.v.), whereas PAF 
      effect was reversed by pretreatment with either the PAF antagonist, BN52021 (1 
      microgram i.c.v.), or the 5-lipoxygenase inhibitors, U-60,257 (75 micrograms 
      i.c.v.) and L-651,392 (10 mg/kg p.o.). PAF was also effective in causing a 3-fold 
      rise in LTC4. Unlike PAF, pyrogens (endotoxin i.c.v. or i.v.; interleukin-1 i.v.) 
      at doses above threshold for fever had no effect on LT levels in CSF, both in the 
      absence and presence of indomethacin pretreatment. We conclude that SP-LTs are a 
      normal constituent of CSF, LTC4, being the major species. The response to PAF 
      accords with a pathogenetic role of the compounds in inflammatory processes and 
      the reactive changes to injury. No evidence was obtained for the involvement of 
      SP-LTs in the central mechanism of fever.
FAU - Hynes, N
AU  - Hynes N
AD  - Research Institute, Hospital for Sick Children, Toronto, Ont, Canada.
FAU - Bishai, I
AU  - Bishai I
FAU - Lees, J
AU  - Lees J
FAU - Coceani, F
AU  - Coceani F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Cerebrospinal Fluid Proteins)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Leukotrienes)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Pyrogens)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arachidonic Acid/administration & dosage/pharmacology
MH  - Body Temperature/drug effects
MH  - Brain Chemistry/drug effects/*physiology
MH  - Cats
MH  - Cerebrospinal Fluid/cytology
MH  - Cerebrospinal Fluid Proteins/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dinoprostone/metabolism
MH  - Female
MH  - In Vitro Techniques
MH  - Injections, Intraventricular
MH  - Leukotrienes/cerebrospinal fluid/*metabolism
MH  - Lipoxygenase Inhibitors/administration & dosage/pharmacology
MH  - Male
MH  - Platelet Activating Factor/administration & dosage/pharmacology
MH  - Pyrogens/pharmacology
MH  - Radioimmunoassay
MH  - Thromboxane B2/metabolism
EDAT- 1991/07/05 00:00
MHDA- 1991/07/05 00:01
CRDT- 1991/07/05 00:00
PHST- 1991/07/05 00:00 [pubmed]
PHST- 1991/07/05 00:01 [medline]
PHST- 1991/07/05 00:00 [entrez]
AID - 0006-8993(91)90222-H [pii]
AID - 10.1016/0006-8993(91)90222-h [doi]
PST - ppublish
SO  - Brain Res. 1991 Jul 5;553(1):4-13. doi: 10.1016/0006-8993(91)90222-h.